| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_42e94091a4fc81b8d0237117707cc7ee |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-04 |
| filingDate |
2001-08-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dc8f87d526c3e7eeb0a5f09f64e48df5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f7256b7b1447d070af33a0e9bcfad865
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7fcb6d6e107878624ce099b56e1730dd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_77bb4eac547a9ea554302544d53d9ed1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bf136d9dd2c03e0619f644f52e804edb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_18a8330bb3f2d3da356b01cc013620ea
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6cdd182963ef0ed261f125ad061006ba |
| publicationDate |
2003-07-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1326612-A1 |
| titleOfInvention |
Gatifloxacin pentahydrate |
| abstract |
There are provided in accordance with the present invention crystalline gatifloxacin pentahydrate represented by the formula (I) in a highly homogeneous form with respect to other crystalline forms thereof. |
| priorityDate |
2000-09-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |